Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO 2023
Biotech
ESMO: Regeneron's Opdualag rival shows 57% response rate
Regeneron is back with follow-up phase 1 data for fianlimab, the company's potential rival to BMS' Opdualag, in advanced melanoma.
Gabrielle Masson
Sep 14, 2024 3:00am
Editor's Corner: Fierce Biotech's top 10 editor's picks for 2023
Dec 27, 2023 7:30am
Biotechs lobby for their identity as drug pricing reforms set in
Jun 28, 2023 7:00am
ASCO: Astellas exec adds gray hair with 3 pending drug approvals
Jun 7, 2023 10:50am
When ASCO dueled with Taylor Swift, we were ready for it
Jun 6, 2023 8:00am
ASCO: Novocure's electric fields extend lung cancer survival
Jun 6, 2023 8:00am
